Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis

By Busse William W.   Massanari Marc   Kianifard Farid   Geba Gregory P.  

Current Medical Research and Opinion, Vol. 23, Iss. 10, 2007-10 ,pp. : 2379-2386

Informa Healthcare

Access to resources Recommend Favorite

Omalizumab in the management of oral corticosteroid-dependent IGE-mediated asthma patients

By Domingo Christian   Moreno Amalia   José Amengual Ma   Montón Concepción   Suárez David   Pomares Xavier  

Current Medical Research and Opinion, Vol. 27, Iss. 1, 2011-01 ,pp. : 45-53

Informa Healthcare

Access to resources Recommend Favorite

Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma

By Milgrom Henry   Fowler-Taylor Angel   Vidaurre Carlos Fernandez   Jayawardene Sumedha  

Current Medical Research and Opinion, Vol. 27, Iss. 1, 2011-01 ,pp. : 163-169

Informa Healthcare

Access to resources Recommend Favorite

The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden

By Dewilde S.   Turk F.   Tambour M.   Sandström T.  

Current Medical Research and Opinion, Vol. 22, Iss. 9, 2006-09 ,pp. : 1765-1776

Informa Healthcare

Access to resources Recommend Favorite

Anti-IgE Therapy with Omalizumab Decreases Endothelin-1 in Exhaled Breath Condensate of Patients with Severe Persistent Allergic Asthma

By  

Respiration, Vol. 80, Iss. 6, 2010-06 ,pp. : 534-542

Karger

Access to resources Recommend Favorite